EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma

Baskaran Subramani iD, Patrick J Conway iD, Aisha Al-Khinji iD, Kun Zhang, Ritu Pandey, Daruka Mahadevan

Cancers · 21.12.2024 · 16 (24) · 4257

DOI: 10.3390/cancers16244257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 21.12.2024. Verfasst von Baskaran Subramani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Aurora (AK) A/B are oncogenic mitotic kinases that when over-expressed are poor prognostic markers in mantle cell lymphoma (MCL). Methods and Results: Alisertib, an AK-A inhibitor, has anti-tumor activity in relapsed/refractory (r/r) MCL patients. We evaluated alisertib plus ibrutinib in MCL to abrogate ibrutinib resistance. Alisertib plus ibrutinib was therapeutically synergistic on both Granta-519 insensitive to ibrutinib and JeKo-1 cells sensitive to ibrutinib. Alisertib decreased PI-3K, BTK, p38, HCK, and RSK kinases, indicative of its multipotent effect on cellular proliferation and growth. A mouse xenograft model of Granta-519 demonstrated that alisertib plus ibrutinib had a comparable anti-tumor response to ibrutinib plus rituximab. However, alisertib plus ibrutinib plus rituximab demonstrated significantly stronger tumor growth inhibition than the doublets. Conclusions: Both double and triple combinations showed enhanced survival versus ibrutinib alone. Ibrutinib insensitivity can be disrupted by alisertib plus ibrutinib in MCL.

Schlagwörter

Stichwörter der Autor:innen

Aurora-ABruton tyrosine kinasemantle cell lymphomarituximab

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Graduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Clinical Translational Science Program, University of Arizona, Tucson, AZ 85721, USA.
  • Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ 85721, USA.

ORCID-Profile: Baskaran Subramani, Patrick J Conway, Aisha Al-Khinji

Zitieren

APA

Subramani, B., Conway, P. J., Al-Khinji, A., Zhang, K., Pandey, R., & Mahadevan, D. (2024). A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma. Cancers, 16(24), 4257. https://doi.org/10.3390/cancers16244257

Vancouver

Subramani B, Conway PJ, Al-Khinji A, Zhang K, Pandey R, Mahadevan D. A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma. Cancers. 2024;16(24):4257. doi:10.3390/cancers16244257

BibTeX
@article{Subramani2024,
  author = {Subramani, Baskaran and Conway, Patrick J and Al-Khinji, Aisha and Zhang, Kun and Pandey, Ritu and Mahadevan, Daruka},
  title = {A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {24},
  pages = {4257},
  doi = {10.3390/cancers16244257}
}
Kostenlos starten →